Eli Lilly and Company – Product Pipeline Review

Global Markets Direct’s, ‘Eli Lilly and Company – Product Pipeline Review – 2016’, provides an overview of the Eli Lilly and Company’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Eli Lilly and Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Eli Lilly and Company

The report provides overview of Eli Lilly and Company including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Eli Lilly and Company’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Eli Lilly and Company’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Eli Lilly and Company’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Eli Lilly and Company

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Eli Lilly and Company’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Eli Lilly and Company Snapshot 7

Eli Lilly and Company Overview 7

Key Information 7

Key Facts 7

Eli Lilly and Company - Research and Development Overview 8

Key Therapeutic Areas 8

Eli Lilly and Company - Pipeline Review 17

Pipeline Products by Stage of Development 17

Pipeline Products - Monotherapy 18

Pipeline Products - Combination Treatment Modalities 19

Pipeline Products - Partnered Products 20

Pipeline Products - Out-Licensed Products 22

Eli Lilly and Company - Pipeline Products Glance 24

Eli Lilly and Company - Late Stage Pipeline Products 24

Eli Lilly and Company - Clinical Stage Pipeline Products 27

Eli Lilly and Company - Early Stage Pipeline Products 31

Eli Lilly and Company - Drug Profiles 33

baricitinib 33

duloxetine hydrochloride DR 36

ixekizumab 38

necitumumab 39

olaratumab 42

ramucirumab 44

cetuximab 50

abemaciclib 57

AMG-5041 59

insulin peglispro 60

LY-2951742 62

odelepran hydrochloride 64

solanezumab 65

tadalafil 67

galunisertib 69

blosozumab 71

edivoxetine hydrochloride 72

emibetuzumab 74

erteberel 75

icrucumab 76

insulin lispro U100 77

landogrozumab 79

LY-2510924 80

LY-2623091 82

LY-2874455 83

LY-2928057 84

LY-2944876 85

LY-3015014 87

LY-3016859 88

LY-3023414 89

LY-3074828 91

merestinib 92

prexasertib 93

ralimetinib mesylate 95

LY-2780301 96

LY-3039478 97

Biologic 6 for Diabetes 98

Biologic for Crohn's Disease 99

Biologic for Diabetic Nephropathy 100

Biologic for Hypoglycemia 101

Biologic for Lupus 102

Biologic for Neutrophilic Dermatosis 103

Biologic for Renal Anemia 104

dulaglutide 105

insulin lispro U200 108

LY-2599666 109

LY-2969822 110

LY-3002813 111

LY-3009120 112

LY-3022855 113

LY-3025876 114

LY-3041658 115

LY-3050258 116

LY-3076226 117

LY-3079514 118

LY-3090106 119

LY-3108743 120

LY-3114062 121

LY-3127760 122

LY-3127804 123

LY-3143753 124

LY-3154207 125

LY-3164530 126

LY-3185643 127

LY-3200327 128

LY-3202626 129

LY-3337641 130

LY-900014 131

Recombinant Protein for Parkinson's Disease 132

Small Molecule 4 for Diabetes 133

cercosporamide 134

CPZEN-45 136

LLY-2707 137

LSN-2463359 138

LSN-2535717 139

LSN-2814617 140

LY-2109761 141

LY-2607540 142

LY-2811376 + LY-3002813 143

LY-2857785 144

LY-344545 145

Monoclonal Antibody Conjugate 2 for Oncology 146

Monoclonal Antibody Conjugate 3 for Oncology 147

Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology 148

ND-09759 149

Small Molecule to Agonize TR-Beta for Dyslipidemia 150

Small Molecule to Antagonize mGlu5 for Pain 151

Drugs for Oncology 152

IC-87201 153

Monoclonal Antibodies for Undisclosed Indication 154

Small Molecule for Type 2 Diabetes 155

Small Molecule to Antagonize EP4 Receptor for Pain and Inflammation 156

Small Molecule to Inhibit MPGES-1 for Inflammation and Pain 157

Eli Lilly and Company - Pipeline Analysis 158

Eli Lilly and Company - Pipeline Products by Target 158

Eli Lilly and Company - Pipeline Products by Route of Administration 165

Eli Lilly and Company - Pipeline Products by Molecule Type 166

Eli Lilly and Company - Pipeline Products by Mechanism of Action 167

Eli Lilly and Company - Recent Pipeline Updates 171

Eli Lilly and Company - Dormant Projects 203

Eli Lilly and Company - Discontinued Pipeline Products 207

Discontinued Pipeline Product Profiles 209

Eli Lilly and Company - Company Statement 220

Eli Lilly and Company - Locations and Subsidiaries 224

Head Office 224

Other Locations & Subsidiaries 224

Eli Lilly and Company - Key Manufacturing Facilities 232

Appendix 233

Methodology 233

Coverage 233

Secondary Research 233

Primary Research 233

Expert Panel Validation 233

Contact Us 233

Disclaimer 234

List of Tables

List of Tables

Eli Lilly and Company, Key Information 15

Eli Lilly and Company, Key Facts 15

Eli Lilly and Company – Pipeline by Indication, 2016 17

Eli Lilly and Company – Pipeline by Stage of Development, 2016 25

Eli Lilly and Company – Monotherapy Products in Pipeline, 2016 26

Eli Lilly and Company – Combination Treatment Modalities in Pipeline, 2016 27

Eli Lilly and Company – Partnered Products in Pipeline, 2016 28

Eli Lilly and Company – Partnered Products/ Combination Treatment Modalities, 2016 29

Eli Lilly and Company – Out-Licensed Products in Pipeline, 2016 30

Eli Lilly and Company – Out-Licensed Products/ Combination Treatment Modalities, 2016 31

Eli Lilly and Company – Pre-Registration, 2016 32

Eli Lilly and Company – Filing rejected/Withdrawn, 2016 33

Eli Lilly and Company – Phase III, 2016 34

Eli Lilly and Company – Phase II, 2016 35

Eli Lilly and Company – Phase I, 2016 37

Eli Lilly and Company – Preclinical, 2016 39

Eli Lilly and Company – Discovery, 2016 40

Eli Lilly and Company – Pipeline by Target, 2016 166

Eli Lilly and Company – Pipeline by Route of Administration, 2016 173

Eli Lilly and Company – Pipeline by Molecule Type, 2016 174

Eli Lilly and Company – Pipeline Products by Mechanism of Action, 2016 175

Eli Lilly and Company – Recent Pipeline Updates, 2016 179

Eli Lilly and Company – Dormant Developmental Projects,2016 211

Eli Lilly and Company – Discontinued Pipeline Products, 2016 215

Eli Lilly and Company, Subsidiaries 232

Eli Lilly and Company, Key Manufacturing Facilities 240

List of Figures

List of Figures

Eli Lilly and Company – Pipeline by Top 10 Indication, 2016 17

Eli Lilly and Company – Pipeline by Stage of Development, 2016 25

Eli Lilly and Company – Monotherapy Products in Pipeline, 2016 26

Eli Lilly and Company – Partnered Products in Pipeline, 2016 28

Eli Lilly and Company – Out-Licensed Products in Pipeline, 2016 30

Eli Lilly and Company – Pipeline by Top 10 Target, 2016 166

Eli Lilly and Company – Pipeline by Route of Administration, 2016 173

Eli Lilly and Company – Pipeline by Molecule Type, 2016 174

Eli Lilly and Company – Pipeline Products by Top 10 Mechanism of Action, 2016 175

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports